Cas:175203-11-9 methyl 3-[(4,5-dichloroimidazol-1-yl)methyl]benzoate manufacturer & supplier

Chemical Name:methyl 3-[(4,5-dichloroimidazol-1-yl)methyl]benzoate

CAS.NO:175203-11-9

Synonyms:methyl 3-[(4,5-dichloroimidazol-1-yl)methyl]benzoate

Molecular Formula:C₁₂H₁₀Cl₂N₂O₂

Molecular Weight:285.12600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:44.12000

Exact Mass:284.01200

LogP:3.02480

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like methyl 3-[(4,5-dichloroimidazol-1-yl)methyl]benzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 3-[(4,5-dichloroimidazol-1-yl)methyl]benzoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 3-[(4,5-dichloroimidazol-1-yl)methyl]benzoate Use and application,methyl 3-[(4,5-dichloroimidazol-1-yl)methyl]benzoate technical grade,usp/ep/jp grade.

Related News: Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact. methyl 3-[(4,5-dichloroimidazol-1-yl)methyl]benzoate manufacturer The upstream industry for the R & D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical bulk drug and chemical pharmaceutical preparation industry. methyl 3-[(4,5-dichloroimidazol-1-yl)methyl]benzoate supplier Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm. methyl 3-[(4,5-dichloroimidazol-1-yl)methyl]benzoate vendor Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact. methyl 3-[(4,5-dichloroimidazol-1-yl)methyl]benzoate factory Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.